Legal Representation
Attorney
ROGER H. BORA
USPTO Deadlines
Next Deadline
130 days remaining
NOA E-Mailed - SOU Required
Due Date
May 14, 2026
Extension Available
Until November 14, 2026
Application History
43 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Nov 6, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 5, 2025 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Nov 5, 2025 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Nov 5, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Apr 26, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Apr 25, 2025 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Apr 25, 2025 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Apr 25, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 13, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 13, 2024 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Nov 13, 2024 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Nov 13, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 11, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 10, 2024 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| May 10, 2024 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| May 10, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 14, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Oct 11, 2023 | EXPT | T | EXPARTE APPEAL TERMINATED | Loading... |
| Oct 10, 2023 | EXDM | T | EXPARTE APPEAL DISMISSED AS MOOT | Loading... |
| Sep 19, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Sep 19, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Aug 30, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Aug 16, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Aug 16, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Aug 16, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jul 31, 2023 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | Loading... |
| Jul 31, 2023 | EXPI | T | EX PARTE APPEAL-INSTITUTED | Loading... |
| Jul 31, 2023 | JURT | T | JURISDICTION RESTORED TO EXAMINING ATTORNEY | Loading... |
| Jul 31, 2023 | EXAF | T | EXPARTE APPEAL RECEIVED AT TTAB | Loading... |
| Apr 27, 2023 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| Apr 27, 2023 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Feb 1, 2023 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Feb 1, 2023 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Feb 1, 2023 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
| Jan 3, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jan 3, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jan 3, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jul 5, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jul 5, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jul 5, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jun 15, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Nov 9, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Nov 1, 2021 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 042
Scientific and technological services in the field of pharmaceuticals featuring scientific testing, analysis and evaluation of blood samples for the purpose of drug development by others, namely, data-driven analytics and reporting to developers of drugs; scientific and technological services in the field of pharmaceuticals featuring scientific testing, analysis and evaluation of blood samples for the purpose of improving quality in the field of healthcare services, specifically for improving the monitoring and diagnostics of quantitative patient drug exposure, the monitoring and diagnostics of patient drug compliance, data-driven analytics and reporting to providers of healthcare services in the field of pharmacovigilance activities, drug dosage recommendations, initial drug prescribing, and drug switching, all for research purposes and not for medical purposes; scientific and technological services in the field of pharmaceuticals featuring pharmacogenomic testing analysis and evaluation of buccal, saliva and other biological samples for the purposes of analyzing how an individual's genetic and non-genetic factors affect their response to drugs, improving drug selection and dosage recommendations, selecting initial and subsequent medications, identifying drug-drug interactions, avoiding adverse drug reactions, developing clinical treatment decision support recommendations, and supporting other medical diagnostic products and prescription drugs; scientific and technological services in the field of pharmaceuticals, namely, scientific testing, research, and analysis for the purpose of determining a patient's disease and drug response phenotype through evaluation of chromatin state, genomic regulatory elements, epigenomics, proteomics, metabolomics, transcriptomics, environmental factors, sociological factors, age, biological sex, ethnicity, and other non-genetic factors to predict pharmacological drug efficacy and adverse drug reaction phenotypes for patients; scientific and technological services in the field of pharmaceuticals featuring scientific testing, analysis and evaluation of buccal, saliva, blood and other biological samples for the purposes of supporting drug clinical trials and research into the field of new drug development and drug repurposing
Additional Information
Pseudo Mark
PREDICT GEN
Classification
International Classes
042